Tumour necrosis factor antagonists and inflammatory bowel diseases: a national practice survey
- 1 October 2009
- journal article
- research article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 30 (8), 854-863
- https://doi.org/10.1111/j.1365-2036.2009.04097.x
Abstract
Although the use of tumour necrosis factor (TNF) antagonists is increasingly codified, several unresolved issues remain. To conduct a French national survey on TNF antagonists use in inflammatory bowel disease (IBD). A postal questionnaire was sent to all French gastroenterologists among whom 450 prescribe TNF antagonists for IBD. Only anti-TNF prescribers were invited to respond. A total of 333 questionnaires could be analysed, which represented a rate of survey completeness of 74%. Scheduled maintenance infliximab treatment was prescribed by 92% of gastroenterologists. In Crohn's disease in remission after 1 year of TNF antagonists, 77.4% of physicians continued treatment. In luminal Crohn's disease, 97% of hospital practitioners introduced infliximab as first-line anti-TNF therapy vs. 78% of physicians with nonhospital activity (P = 0.002); only 22.5% of gastroenterologists opted for adalimumab as first-line therapy. In Crohn's disease in remission after 6 months of azathioprine in combination with infliximab, 63.8% of practitioners discontinued azathioprine. In case of pregnancy during anti-TNF treatment, 35.1% of physicians discontinued therapy at the time of conception and did not administer anti-TNF therapy during pregnancy. The attitudes of French gastroenterologists generally reflect the recommendations regarding the use of anti-TNF and concomitant immunosuppressive therapy in IBD.Keywords
This publication has 26 references indexed in Scilit:
- A Safety Assessment of Tumor Necrosis Factor Antagonists During Pregnancy: A Review of the Food and Drug Administration DatabaseThe Journal of Rheumatology, 2009
- TNF antagonists in the treatment of inflammatory bowel disease: Results of a survey of gastroenterologists in the French region of LorraineGastroentérologie Clinique Et Biologique, 2008
- Infliximab treatment for symptomatic Crohn’s disease stricturesAlimentary Pharmacology & Therapeutics, 2008
- Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohortGut, 2008
- Hepatosplenic T cell lymphoma in inflammatory bowel diseaseGut, 2008
- Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM TrialGastroenterology, 2007
- Case Report: Evidence for Transplacental Transfer of Maternally Administered Infliximab to the NewbornClinical Gastroenterology and Hepatology, 2006
- Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's diseaseGastrointestinal Endoscopy, 2006
- Human Anti–Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease: the CLASSIC-I TrialGastroenterology, 2006
- Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)Gastroenterology, 1995